(AOF) – The editorial staff has clarified the article published this Wednesday about Inventiva. Inventiva shows 11 million euros of cash and cash equivalents as of March 31. Short-term deposits reach 0.1 million euros and long-term deposits 19.1 million euros, giving a total of 31 million euros. The long-term deposit with a duration of two years is, however, accessible before expiry of the term with 31 days’ notice and is considered liquid by the company.
The biotech specializing in the clinical development of small molecules administered orally for the treatment of non-alcoholic steatohepatitis (“NASH”) estimates that these funds should allow it to finance its activities until the start of the third quarter of 2024. Inventiva specifies that it did not generate revenue in the first quarter of 2024, as it did for the first quarter of 2023.
The first visit of the last patient of the Phase III NATIV3 clinical study evaluating the product lanifibranor in MASH/NASH is planned for the first half of 2024.
AOF – LEARN MORE
Learn more about the Pharmacy sector
Oncology, priority of pharmaceutical giants
Sanofi’s stock market disappointment recorded at the end of October 2023 underlines the new direction for the group, which has now set oncology as its number 1 priority. Efforts in this segment, where therapies are advancing the fastest, notably involve investments in R&D which weigh on profitability. Sanofi therefore announced a drop in its earnings per share in 2024 and the abandonment of its objective of an operating margin of 32% in 2025. Merck has just unveiled a new alliance. It will pay up to $22 billion to the Japanese group Daiichi Sankyo as part of a partnership on experimental cancer treatments. While some experts estimate that the United States represents nearly half of global oncology spending (drugs and treatments), or $196 billion in 2022, Chinese spending in this area has more than doubled in five years, going from 5 to 11.8 billion dollars.